Federal contract award
75F40123C00211
THE OBJECTIVES OF THE PROPOSED STUDY ARE TO EXAMINE THE EFFECTS OF POSTNATAL MANAGEMENT APPROACHES (NON-PHARMACOLOGICAL, INCLUDING ESC VERSUS OPIOID REPLACEMENT PHARMACOTHERAPY) AND THE TIMING AND DURATION OF GESTATIONAL OPIOID EXPOSURE ON IN-HOSPITA
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | FIRM FIXED PRICE |
| Obligations | $520.6K |
| Current contract value | $520.6K |
| Potential contract value / ceiling | $520.6K |
| Start date | Sep 25, 2023 |
| Current end date | Jun 27, 2025 |
| Potential end date | Sep 29, 2025 |
| Latest award activity | Nov 20, 2025 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Nov 20, 2025 | P00005 | $-340.4K | THE PURPOSE OF THIS MODIFICATION IS TO DE-OBLIGATE FUNDS, CANCEL NON-FUNDED ITEMS 3 & 4, THEN CLOSE OUT THE CONTRACT. |
| Jun 27, 2025 | P00004 | $0 | EOI::COLUMBIAU/PPP::EOI |
| Mar 7, 2025 | P00003 | $0 | EOI:: IMPLEMENTING THE PRESIDENT'S DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE :: EOI |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 20, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 20, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Terry Frederick | Contact | Terry.Frederick@fda.hhs.gov 301-348-1814 | Source | Jan 7, 2022 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | Nov 10, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 240-402-8639 | Source | Nov 10, 2021 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.